skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Mass Spectrometry-based Assay for High Throughput and High Sensitivity Biomarker Verification

Abstract

Searching for disease specific biomarkers has become a major undertaking in the biomedical research field as the effective diagnosis, prognosis and treatment of many complex human diseases are largely determined by the availability and the quality of the biomarkers. A successful biomarker as an indicator to a specific biological or pathological process is usually selected from a large group of candidates by a strict verification and validation process. To be clinically useful, the validated biomarkers must be detectable and quantifiable by the selected testing techniques in their related tissues or body fluids. Due to its easy accessibility, protein biomarkers would ideally be identified in blood plasma or serum. However, most disease related protein biomarkers in blood exist at very low concentrations (<1ng/mL) and are “masked” by many none significant species at orders of magnitude higher concentrations. The extreme requirements of measurement sensitivity, dynamic range and specificity make the method development extremely challenging. The current clinical protein biomarker measurement primarily relies on antibody based immunoassays, such as ELISA. Although the technique is sensitive and highly specific, the development of high quality protein antibody is both expensive and time consuming. The limited capability of assay multiplexing also makes the measurement an extremelymore » low throughput one rendering it impractical when hundreds to thousands potential biomarkers need to be quantitatively measured across multiple samples. Mass spectrometry (MS)-based assays have recently shown to be a viable alternative for high throughput and quantitative candidate protein biomarker verification. Among them, the triple quadrupole MS based assay is the most promising one. When it is coupled with liquid chromatography (LC) separation and electrospray ionization (ESI) source, a triple quadrupole mass spectrometer operating in a special selected reaction monitoring (SRM) mode, also known as multiple reaction monitoring (MRM), is capable of quantitatively measuring hundreds of candidate protein biomarkers from a relevant clinical sample in a single analysis. The specificity, reproducibility and sensitivity could be as good as ELISA. Furthermore, SRM MS can also quantify protein isoforms and post-translational modifications, for which traditional antibody-based immunoassays often don’t exist.« less

Authors:
;
Publication Date:
Research Org.:
Pacific Northwest National Laboratory (PNNL), Richland, WA (US), Environmental Molecular Sciences Laboratory (EMSL)
Sponsoring Org.:
USDOE
OSTI Identifier:
1378050
Report Number(s):
PNNL-SA-105981
47301; 400412000
DOE Contract Number:
AC05-76RL01830
Resource Type:
Book
Resource Relation:
Related Information: Protein Analysis Using Mass Spectrometry: Accelerating Protein Biotherapeutics from Lab to Patient
Country of Publication:
United States
Language:
English
Subject:
Environmental Molecular Sciences Laboratory

Citation Formats

Guo, Xuejiang, and Tang, Keqi. Mass Spectrometry-based Assay for High Throughput and High Sensitivity Biomarker Verification. United States: N. p., 2017. Web. doi:10.1002/9781119371779.ch9.
Guo, Xuejiang, & Tang, Keqi. Mass Spectrometry-based Assay for High Throughput and High Sensitivity Biomarker Verification. United States. doi:10.1002/9781119371779.ch9.
Guo, Xuejiang, and Tang, Keqi. Wed . "Mass Spectrometry-based Assay for High Throughput and High Sensitivity Biomarker Verification". United States. doi:10.1002/9781119371779.ch9.
@article{osti_1378050,
title = {Mass Spectrometry-based Assay for High Throughput and High Sensitivity Biomarker Verification},
author = {Guo, Xuejiang and Tang, Keqi},
abstractNote = {Searching for disease specific biomarkers has become a major undertaking in the biomedical research field as the effective diagnosis, prognosis and treatment of many complex human diseases are largely determined by the availability and the quality of the biomarkers. A successful biomarker as an indicator to a specific biological or pathological process is usually selected from a large group of candidates by a strict verification and validation process. To be clinically useful, the validated biomarkers must be detectable and quantifiable by the selected testing techniques in their related tissues or body fluids. Due to its easy accessibility, protein biomarkers would ideally be identified in blood plasma or serum. However, most disease related protein biomarkers in blood exist at very low concentrations (<1ng/mL) and are “masked” by many none significant species at orders of magnitude higher concentrations. The extreme requirements of measurement sensitivity, dynamic range and specificity make the method development extremely challenging. The current clinical protein biomarker measurement primarily relies on antibody based immunoassays, such as ELISA. Although the technique is sensitive and highly specific, the development of high quality protein antibody is both expensive and time consuming. The limited capability of assay multiplexing also makes the measurement an extremely low throughput one rendering it impractical when hundreds to thousands potential biomarkers need to be quantitatively measured across multiple samples. Mass spectrometry (MS)-based assays have recently shown to be a viable alternative for high throughput and quantitative candidate protein biomarker verification. Among them, the triple quadrupole MS based assay is the most promising one. When it is coupled with liquid chromatography (LC) separation and electrospray ionization (ESI) source, a triple quadrupole mass spectrometer operating in a special selected reaction monitoring (SRM) mode, also known as multiple reaction monitoring (MRM), is capable of quantitatively measuring hundreds of candidate protein biomarkers from a relevant clinical sample in a single analysis. The specificity, reproducibility and sensitivity could be as good as ELISA. Furthermore, SRM MS can also quantify protein isoforms and post-translational modifications, for which traditional antibody-based immunoassays often don’t exist.},
doi = {10.1002/9781119371779.ch9},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Wed Jun 14 00:00:00 EDT 2017},
month = {Wed Jun 14 00:00:00 EDT 2017}
}

Book:
Other availability
Please see Document Availability for additional information on obtaining the full-text document. Library patrons may search WorldCat to identify libraries that hold this book.

Save / Share:
  • In this review, we describe the technological basis and progress towards a new global proteomics strategy that uses peptide accurate mass measurements augmented by information from separations (e.g. LC retention times) to provide large improvements in sensitivity, dynamic range, comprehensiveness and throughput. The use of ?accurate mass and time? (AMT) tags serves to eliminate the need for routine MS/MS measurements [#4109]. As the case study, we use our own research efforts to illustrate the role of AMTs within the broader context of a state-of-the-art proteomics effort. Our strategy exploits high-resolution capillary LC separations combined with Fourier transform ion cyclotron resonancemore » mass spectrometry (FTICR). AMTs represent peptide biomarkers and can be used to confidently identify proteins based on the high mass measurement accuracy provided by FTICR combined with LC elution times. Once identified using MS/MS, these biomarkers provide the foundation for subsequent high throughput studies using only AMT tags to identify and quantify the proteins expressed within a cell system. Key attractions of this approach include the feasibility of completely automated high confidence protein identifications, extensive proteome coverage, and the capability for exploiting stable-isotope labeling methods for high precision abundance measurements [#4019]. Additional developments described in this review include methods for more effective coverage of membrane proteins [#4184], for dynamic range expansion of proteome measurements [#4012], and for multi-stage separations that promise to enable more focused analyses, further extend the quality of measurements, and also extend measurements to more complex proteomes.« less
  • Biomarkers potentially play a crucial role in early disease diagnosis, prognosis and targeted therapy. In the past decade, mass spectrometry based proteomics has become increasingly important in biomarker development due to large advances in technology and associated methods. This chapter mainly focuses on the application of broad (e.g. shotgun) proteomics in biomarker discovery and the utility of targeted proteomics in biomarker verification and validation. A range of mass spectrometry methodologies are discussed emphasizing their efficacy in the different stages in biomarker development, with a particular emphasis on blood biomarker development.
  • For certain nuclear reactors, the fuel consists of highly enriched uranium fabricated into flat or bowed plates. Typically, these plates are relatively thin so that a significant percentage of the /sup 235/U gamma rays penetrate the fuel cladding. When the measurement conditions are properly controlled and corrections are made for variations in the attenuation of the gamma rays, a measurement of the /sup 235/U gamma rays can be used as an acceptable measurement of the distribution and the total /sup 235/U content of each fuel plate. In lieu of assaying the product fuel plates, fuel plate core compacts may bemore » assayed through the procedures detailed in this guide, provided steps are taken to ensure the traceability and integrity of encapsulation of each assayed fuel place core compact. This guide describes features of a gamma ray spectrometry system acceptable to the Regulatory staff for nondestructive assay of high-enrichment uranium fuel plates or fuel plate core compacts.« less